Ongericimab clinical trials
Also written JS002.
How each study uses ongericimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ongericimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 0 · Other 8
Shanghai Junshi Bioscience Co., Ltd. (7) · Shanghai Pudong Hospital (1)
Often tested with
Tested in the same studies.
Folfox protocol (1) · FOLFIRI-Ziv-aflibercept Regimen (1) · FOLFIRI Regimen (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test ongericimab.
- Jul 2027Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II TrialPhase 2 · Shanghai Pudong Hospital
Studies
Open first, then newest update. How each study uses ongericimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Standard Second-line Therapy With ONgericimab and TOripalimab in pMMR/MSS Colorectal Cancer: a Single-arm Phase II TrialRecruitingPhase 2Shanghai Pudong HospitalNCT07106034Written as Ongericimab + Toripalimab + Bevacizumab + FOLFOXHow we know
- Efficacy and Safety of JS002 as Monotherapy in Patients With Primary Hypercholesterolaemia and Mixed DyslipidemiaRecruitingPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT05621070Written as JS002How we know
- A Pharmacokinetic Study of JS002 in Healthy SubjectsCompletedPhase 1Shanghai Junshi Bioscience Co., Ltd.NCT05859529Written as JS002How we know
- To Evaluate the Efficacy and Safety of JS002 in HoFH PatientsCompletedPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT04515927Written as JS002How we know
- A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).CompletedPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT05325203Written as OngericimabHow we know
- The Safety and Efficacy of Multiple-dose of JS002 in Subject With HyperlipidemiaCompletedPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT04781114Written as JS002How we know
- The Efficacy and Safety of JS002 PFS and AI in Patients With Primary Hypercholesterolemia and Mixed HyperlipidemiaCompletedPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT05532800Written as JS002How we know
- A Single Dose Escalation Study of PCSK9 Inhibitor (JS002) in Health SubjectsCompletedPhase 1Shanghai Junshi Bioscience Co., Ltd.NCT04197817Written as JS002How we know
Codes
What other systems call ongericimab · ClinicalTrials.gg INT018410
- UNII (FDA) X126G5DZ36ONGERICIMABOne source FDA
- NCI Thesaurus C174940OngericimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | X126G5DZ36 | ONGERICIMAB | One source FDA |
| NCI Thesaurus | C174940 | Ongericimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.